Science

Pipeline

Pipeline Overview

LiPlaCis®

Enables a more targeted delivery at the tumor site of cisplatin
Phase
1
2
2/pivotal

LiPlaCis

no text

LiPlaCis® is a unified product consisting of the LiPlaCis drug and its DRP®, Oncology Venture’s unique companion diagnostic

The LiPlaCis drug is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin, which has documented efficacy in numerous tumor types.

The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed.

2X-121

2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2
Phase
1
2
3

2X-121

no text

2X-121 is a unified product consisting of a PARP inhibitor and its DRP®, Oncology Venture’s unique companion diagnostic

The drug is an investigational, orally-available small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.

Dovitinib

Dovitinib is an investigational orally active small molecule multi-kinase inhibitor that exhibits potent activity against multiple RTKs involved in tumor growth and angiogenesis.
Phase
1
2
3

Dovitinib

no text

Dovitinib is a unified product consisting of a active small molecule multi-kinase inhibitor and its DRP®, Oncology Venture’s unique companion diagnostic

The dovitinib drug binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells.

2X-111

Glutathione-enhanced, PEGylated Liposomal Doxorubicin
Phase
1
2
3

2X-111

no text

2X-111 is a unified product consisting of liposomal doxorubicin and its accompanying DRP®, Oncology Venture’s unique companion diagnostic

This novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier. 

Irofulven

This drug candidate is a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor.
Phase
1
2
3

Irofulven

no text

 

Irofulven is a unified product consisting of a synthetic drug and an accompanying DRP®, Oncology Venture’s unique companion diagnostic.

The irofulven drug alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity.

APO010

APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma, a systemic malignancy in the blood that affects plasma cells.
Phase
1
2
3

APO010

no text

APO010  is a unified product consisting of a systemic chemotherapeutic treatment and its DRP®, Oncology Venture’s unique companion diagnostic.

The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis.